Skip to main content

Table 9 Safety profile

From: Xuan Bai Cheng Qi formula as an adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs: a multicenter, randomized, double-blind, placebo-controlled clinical trial

Variablesa

XBCQb(n = 122)

Controlb(n = 122)

P- valuea

 

Day 1 (Baseline)

Day 10 (End)

Day 1 (Baseline)

Day 10 (End)

 

WBC (109/L)

8.33 (3.49)

7.51 (2.81)

9.38 (7.95)

7.53 (3.11)

.843

HB (g/L)

138.2 (24.0)

138.6 (31.0)

136.3 (28.1)

134.3 (28.1)

.310

RBC (1012/L)

4.39 (0.65)

4.38 (0.64)

4.33 (0.61)

4.27 (0.57)

.263

PLT (109/L)

198.4 (62.4)

210.4 (78.7)

209.4 (76.9)

207.5 (68.4)

.178

NEUT (%)

69.6 (14.4)

64.7 (12.9)

68.9 (14.9)

62.1 (13.4)

.111

ALT (U/L)

21.0 (11.1)

22.2 (12.1)

21.9 (16.3)

22.5 (14.1)

.920

BUN (mmol/L)

5.6 (1.6)

5.7 (2.4)

6.1 (2.8)

5.8 (2.8)

.511

CR ( μmmol/L)

75.4 (20.4)

74.0 (21.5)

85.2 (46.5)

80.3 (35.9)

.863

BUN (n)c

27 (122)

32 (122)

15 (122)

7 (122)

.116

ECG (n)c

56 (122)

45 (122)

57 (122)

47 (122)

.895

  1. Abbreviations: ALT alanine aminotransferase, BUN blood urea nitrogen, Cr creatinine, ECG electrocardiogram, HB hemoglobin, NEUT neutrophilic granulocyte, PLT platelets, RBC red blood cell, WBC white blood cell.
  2. aCovariance analysis for between group after treatment. bData presented as mean (SD).
  3. cChi-square test for between group after treatment.